Drugs.com - FDA MedWatch Alerts

FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize

Audience: Industry October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022...

Apr 26, 2025 - 14:23
 0
FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
Audience: Industry October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022...
Read More

Tags:

Previous Article

Staska Pharmaceuticals, Inc. Issues Recall of Ascorbic Acid Solution for Injecti...

Next Article

FDA is Alerting Patients and Health Care Professionals About the Voluntary Withd...

Related Posts

Drug Safety Communication: FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause

Drug Safety Communication: FDA Adds Warning About Rare ...

Apr 26, 2025  0

FDA Warns Patients and Health Care Professionals Not to Use Compounded Drugs from Fullerton Wellness

FDA Warns Patients and Health Care Professionals Not to...

Apr 26, 2025  0

Voluntary Lot Withdrawals of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous (IGSC) Due to Increased Reports of Allergic/Hypersensitivity Reactions

Voluntary Lot Withdrawals of Immune Globulin Intravenou...

Apr 26, 2025  0